THE IMPACT OF TRIKAFTA (ELEXACAFTOR/IVACAFTOR/TEZACAFTOR) ON PATIENTS WITH CYSTIC FIBROSIS WITH COVID-19

Detalles Bibliográficos
Autores principales: MILES, B., CHACKO, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Chest Physicians. Published by Elsevier Inc. 2022
Materias:
Genetic and Developmental Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212442/
http://dx.doi.org/10.1016/j.chest.2021.12.325
_version_ 1784730593931558912
author MILES, B.
CHACKO, J.
author_facet MILES, B.
CHACKO, J.
author_sort MILES, B.
collection PubMed
description
format Online
Article
Text
id pubmed-9212442
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American College of Chest Physicians. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-92124422022-06-22 THE IMPACT OF TRIKAFTA (ELEXACAFTOR/IVACAFTOR/TEZACAFTOR) ON PATIENTS WITH CYSTIC FIBROSIS WITH COVID-19 MILES, B. CHACKO, J. Chest Genetic and Developmental Disorders American College of Chest Physicians. Published by Elsevier Inc. 2022-06 2022-06-20 /pmc/articles/PMC9212442/ http://dx.doi.org/10.1016/j.chest.2021.12.325 Text en Copyright © 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Genetic and Developmental Disorders
MILES, B.
CHACKO, J.
THE IMPACT OF TRIKAFTA (ELEXACAFTOR/IVACAFTOR/TEZACAFTOR) ON PATIENTS WITH CYSTIC FIBROSIS WITH COVID-19
title THE IMPACT OF TRIKAFTA (ELEXACAFTOR/IVACAFTOR/TEZACAFTOR) ON PATIENTS WITH CYSTIC FIBROSIS WITH COVID-19
title_full THE IMPACT OF TRIKAFTA (ELEXACAFTOR/IVACAFTOR/TEZACAFTOR) ON PATIENTS WITH CYSTIC FIBROSIS WITH COVID-19
title_fullStr THE IMPACT OF TRIKAFTA (ELEXACAFTOR/IVACAFTOR/TEZACAFTOR) ON PATIENTS WITH CYSTIC FIBROSIS WITH COVID-19
title_full_unstemmed THE IMPACT OF TRIKAFTA (ELEXACAFTOR/IVACAFTOR/TEZACAFTOR) ON PATIENTS WITH CYSTIC FIBROSIS WITH COVID-19
title_short THE IMPACT OF TRIKAFTA (ELEXACAFTOR/IVACAFTOR/TEZACAFTOR) ON PATIENTS WITH CYSTIC FIBROSIS WITH COVID-19
title_sort impact of trikafta (elexacaftor/ivacaftor/tezacaftor) on patients with cystic fibrosis with covid-19
topic Genetic and Developmental Disorders
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212442/
http://dx.doi.org/10.1016/j.chest.2021.12.325
work_keys_str_mv AT milesb theimpactoftrikaftaelexacaftorivacaftortezacaftoronpatientswithcysticfibrosiswithcovid19
AT chackoj theimpactoftrikaftaelexacaftorivacaftortezacaftoronpatientswithcysticfibrosiswithcovid19
AT milesb impactoftrikaftaelexacaftorivacaftortezacaftoronpatientswithcysticfibrosiswithcovid19
AT chackoj impactoftrikaftaelexacaftorivacaftortezacaftoronpatientswithcysticfibrosiswithcovid19

Ejemplares similares